1ira › Citations

A new cytokine-receptor binding mode revealed by the crystal structure of the IL-1 receptor with an antagonist.

Schreuder H, Tardif C, Trump-Kallmeyer S, Soffientini A, Sarubbi E, Akeson A, Bowlin T, Yanofsky S, Barrett RW
Nature 386 194-200 (1997)
Cited: 149 times
EuropePMC logo PMID: 9062194

Abstract

Inflammation, regardless of whether it is provoked by infection or by tissue damage, starts with the activation of macrophages which initiate a cascade of inflammatory responses by producing the cytokines interleukin-1 (IL-1) and tumour necrosis factor-alpha (ref. 1). Three naturally occurring ligands for the IL-1 receptor (IL1R) exist: the agonists IL-1alpha and IL-1beta and the IL-1-receptor antagonist IL1RA (ref. 2). IL-1 is the only cytokine for which a naturally occurring antagonist is known. Here we describe the crystal structure at 2.7 A resolution of the soluble extracellular part of type-I IL1R complexed with IL1RA. The receptor consists of three immunoglobulin-like domains. Domains 1 and 2 are tightly linked, but domain three is completely separate and connected by a flexible linker. Residues of all three domains contact the antagonist and include the five critical IL1RA residues which were identified by site-directed mutagenesis. A region that is important for biological function in IL-1beta, the 'receptor trigger site' is not in direct contact with the receptor in the IL1RA complex. Modelling studies suggest that this IL-1beta trigger site might induce a movement of domain 3.

Reviews - 1ira mentioned but not cited (3)

  1. Structural Basis of IL-1 Family Cytokine Signaling. Fields JK, Günther S, Sundberg EJ. Front Immunol 10 1412 (2019)
  2. Structural biology of the IL-1 superfamily: key cytokines in the regulation of immune and inflammatory responses. Krumm B, Xiang Y, Deng J. Protein Sci 23 526-538 (2014)
  3. The Therapeutic Prospects of Targeting IL-1R1 for the Modulation of Neuroinflammation in Central Nervous System Disorders. Luís JP, Simões CJV, Brito RMM. Int J Mol Sci 23 1731 (2022)

Articles - 1ira mentioned but not cited (34)

  1. Protein-protein docking benchmark version 3.0. Hwang H, Pierce B, Mintseris J, Janin J, Weng Z. Proteins 73 705-709 (2008)
  2. Structural interactions of fibroblast growth factor receptor with its ligands. Stauber DJ, DiGabriele AD, Hendrickson WA. Proc Natl Acad Sci U S A 97 49-54 (2000)
  3. Structure and intracellular targeting of the SARS-coronavirus Orf7a accessory protein. Nelson CA, Pekosz A, Lee CA, Diamond MS, Fremont DH. Structure 13 75-85 (2005)
  4. Cross-link guided molecular modeling with ROSETTA. Kahraman A, Herzog F, Leitner A, Rosenberger G, Aebersold R, Malmström L. PLoS One 8 e73411 (2013)
  5. SwarmDock and the use of normal modes in protein-protein docking. Moal IH, Bates PA. Int J Mol Sci 11 3623-3648 (2010)
  6. Design of a superior cytokine antagonist for topical ophthalmic use. Hou J, Townson SA, Kovalchin JT, Masci A, Kiner O, Shu Y, King BM, Schirmer E, Golden K, Thomas C, Garcia KC, Zarbis-Papastoitsis G, Furfine ES, Barnes TM. Proc Natl Acad Sci U S A 110 3913-3918 (2013)
  7. Molecular characteristics of fibroblast growth factor-fibroblast growth factor receptor-heparin-like glycosaminoglycan complex. Venkataraman G, Raman R, Sasisekharan V, Sasisekharan R. Proc Natl Acad Sci U S A 96 3658-3663 (1999)
  8. MEGADOCK: an all-to-all protein-protein interaction prediction system using tertiary structure data. Ohue M, Matsuzaki Y, Uchikoga N, Ishida T, Akiyama Y. Protein Pept Lett 21 766-778 (2014)
  9. Identification of potential small molecule allosteric modulator sites on IL-1R1 ectodomain using accelerated conformational sampling method. Yang CY. PLoS One 10 e0118671 (2015)
  10. Protein-protein binding site identification by enumerating the configurations. Guo F, Li SC, Wang L, Zhu D. BMC Bioinformatics 13 158 (2012)
  11. Anti-inflammatory properties of a novel peptide interleukin 1 receptor antagonist. Klementiev B, Li S, Korshunova I, Dmytriyeva O, Pankratova S, Walmod PS, Kjær LK, Dahllöf MS, Lundh M, Christensen DP, Mandrup-Poulsen T, Bock E, Berezin V. J Neuroinflammation 11 27 (2014)
  12. Pre- and post-docking sampling of conformational changes using ClustENM and HADDOCK for protein-protein and protein-DNA systems. Kurkcuoglu Z, Bonvin AMJJ. Proteins 88 292-306 (2020)
  13. DrugScorePPI knowledge-based potentials used as scoring and objective function in protein-protein docking. Krüger DM, Ignacio Garzón J, Chacón P, Gohlke H. PLoS One 9 e89466 (2014)
  14. Prediction of Protein-Protein Interaction Sites Using Convolutional Neural Network and Improved Data Sets. Xie Z, Deng X, Shu K. Int J Mol Sci 21 E467 (2020)
  15. A relation between the principal axes of inertia and ligand binding. Foote J, Raman A. Proc Natl Acad Sci U S A 97 978-983 (2000)
  16. Conformational Sampling and Binding Site Assessment of Suppression of Tumorigenicity 2 Ectodomain. Yang CY, Delproposto J, Chinnaswamy K, Brown WC, Wang S, Stuckey JA, Wang X. PLoS One 11 e0146522 (2016)
  17. Neutralizing anti-IL-1 receptor antagonist autoantibodies induce inflammatory and fibrotic mediators in IgG4-related disease. Jarrell JA, Baker MC, Perugino CA, Liu H, Bloom MS, Maehara T, Wong HH, Lanz TV, Adamska JZ, Kongpachith S, Sokolove J, Stone JH, Pillai SS, Robinson WH. J Allergy Clin Immunol 149 358-368 (2022)
  18. PASylation of IL-1 receptor antagonist (IL-1Ra) retains IL-1 blockade and extends its duration in mouse urate crystal-induced peritonitis. Powers NE, Swartzwelter B, Marchetti C, de Graaf DM, Lerchner A, Schlapschy M, Datar R, Binder U, Edwards CK, Skerra A, Dinarello CA. J Biol Chem 295 868-882 (2020)
  19. How to use not-always-reliable binding site information in protein-protein docking prediction. Li L, Huang Y, Xiao Y. PLoS One 8 e75936 (2013)
  20. Cryo-EM Data Are Superior to Contact and Interface Information in Integrative Modeling. de Vries SJ, Chauvot de Beauchêne I, Schindler CE, Zacharias M. Biophys J 110 785-797 (2016)
  21. Evaluation of Anti-inflammatory and Regenerative Efficiency of Naringin and Naringenin in Degenerated Human Nucleus Pulposus Cells: Biological and Molecular Modeling Studies. Devraj VM, Vemuri SK, Banala RR, Gunda SK, Av GR, Gpv S. Asian Spine J 13 875-889 (2019)
  22. A Closer Look at Dexamethasone and the SARS-CoV-2-Induced Cytokine Storm: In Silico Insights of the First Life-Saving COVID-19 Drug. Morgan P, Arnold SJ, Hsiao NW, Shu CW. Antibiotics (Basel) 10 1507 (2021)
  23. Comparative Analyses of the Conformational Dynamics Between the Soluble and Membrane-Bound Cytokine Receptors. Yang CY. Sci Rep 10 7399 (2020)
  24. Direct binding to integrins and loss of disulfide linkage in interleukin-1β (IL-1β) are involved in the agonistic action of IL-1β. Takada YK, Yu J, Fujita M, Saegusa J, Wu CY, Takada Y. J Biol Chem 292 20067-20075 (2017)
  25. Predicting Protein-Protein Interaction Sites Using Sequence Descriptors and Site Propensity of Neighboring Amino Acids. Kuo TH, Li KB. Int J Mol Sci 17 E1788 (2016)
  26. Domain-Based Protein Docking with Extremely Large Conformational Changes. Christoffer C, Kihara D. J Mol Biol 434 167820 (2022)
  27. Detecting protein conformational changes in interactions via scaling known structures. Guo F, Li SC, Ma W, Wang L. J Comput Biol 20 765-779 (2013)
  28. Determining Complex Structures using Docking Method with Single Particle Scattering Data. Wang H, Liu H. Front Mol Biosci 4 23 (2017)
  29. Understanding the diverse functions of Huatan Tongluo Fang on rheumatoid arthritis from a pharmacological perspective. Zheng C, Qiu M, Xu X, Ye H, Zhang Q, Li Y, Liu X, Chen J. Exp Ther Med 12 87-94 (2016)
  30. Mechanism Prediction of Astragalus membranaceus against Cisplatin-Induced Kidney Damage by Network Pharmacology and Molecular Docking. Jia C, Pan X, Wang B, Wang P, Wang Y, Chen R. Evid Based Complement Alternat Med 2021 9516726 (2021)
  31. X-ray crystal structure localizes the mechanism of inhibition of an IL-36R antagonist monoclonal antibody to interaction with Ig1 and Ig2 extra cellular domains. Larson ET, Brennan DL, Hickey ER, Ganesan R, Kroe-Barrett R, Farrow NA. Protein Sci 29 1679-1686 (2020)
  32. Conformational Dynamics of the Soluble and Membrane-Bound Forms of Interleukin-1 Receptor Type-1: Insights into Linker Flexibility and Domain Orientation. Luís JP, Mata AI, Simões CJV, Brito RMM. Int J Mol Sci 23 2599 (2022)
  33. Vibrational spectroscopy, quantum computational and molecular docking studies on 2-chloroquinoline-3-carboxaldehyde. Saral A, Sudha P, Muthu S, Sevvanthi S, Sangeetha P, Selvakumari S. Heliyon 7 e07529 (2021)
  34. iScore: An MPI supported software for ranking protein-protein docking models based on a random walk graph kernel and support vector machines. Renaud N, Jung Y, Honavar V, Geng C, Bonvin AMJJ, Xue LC. SoftwareX 11 100462 (2020)


Reviews citing this publication (34)

  1. Proinflammatory cytokines. Dinarello CA. Chest 118 503-508 (2000)
  2. Anti-inflammatory cytokines. Opal SM, DePalo VA. Chest 117 1162-1172 (2000)
  3. Interleukin-1 receptor antagonist: role in biology. Arend WP, Malyak M, Guthridge CJ, Gabay C. Annu Rev Immunol 16 27-55 (1998)
  4. Cytokine storm and sepsis disease pathogenesis. Chousterman BG, Swirski FK, Weber GF. Semin Immunopathol 39 517-528 (2017)
  5. Platelets as immune cells: bridging inflammation and cardiovascular disease. von Hundelshausen P, Weber C. Circ Res 100 27-40 (2007)
  6. Interleukin-1. Dinarello CA. Cytokine Growth Factor Rev 8 253-265 (1997)
  7. The interleukin-1 receptor/Toll-like receptor superfamily: 10 years of progress. O'Neill LA. Immunol Rev 226 10-18 (2008)
  8. The interleukin-1 receptor/Toll-like receptor superfamily: signal transduction during inflammation and host defense. Dunne A, O'Neill LA. Sci STKE 2003 re3 (2003)
  9. Role of cytokines as a double-edged sword in sepsis. Chaudhry H, Zhou J, Zhong Y, Ali MM, McGuire F, Nagarkatti PS, Nagarkatti M. In Vivo 27 669-684 (2013)
  10. The family of the interleukin-1 receptors. Boraschi D, Italiani P, Weil S, Martin MU. Immunol Rev 281 197-232 (2018)
  11. The interleukin-1 receptor family. Boraschi D, Tagliabue A. Semin Immunol 25 394-407 (2013)
  12. Interleukin-1 Beta-A Friend or Foe in Malignancies? Bent R, Moll L, Grabbe S, Bros M. Int J Mol Sci 19 E2155 (2018)
  13. The Class II cytokine receptor (CRF2) family: overview and patterns of receptor-ligand interactions. Langer JA, Cutrone EC, Kotenko S. Cytokine Growth Factor Rev 15 33-48 (2004)
  14. The IL-1 cytokine family and its role in inflammation and fibrosis in the lung. Borthwick LA. Semin Immunopathol 38 517-534 (2016)
  15. IL-1 and IL-18 receptors, and their extended family. Sims JE. Curr Opin Immunol 14 117-122 (2002)
  16. Interleukin-1 (IL-1) family of cytokines: role in type 2 diabetes. Banerjee M, Saxena M. Clin Chim Acta 413 1163-1170 (2012)
  17. Structural analysis of receptor tyrosine kinases. Hubbard SR. Prog Biophys Mol Biol 71 343-358 (1999)
  18. Interleukin 1 signal transduction--current concepts and relevance to periodontitis. Boch JA, Wara-aswapati N, Auron PE. J Dent Res 80 400-407 (2001)
  19. Minimized proteins. Cunningham BC, Wells JA. Curr Opin Struct Biol 7 457-462 (1997)
  20. Advances in integrative modeling of biomolecular complexes. Karaca E, Bonvin AM. Methods 59 372-381 (2013)
  21. Special aspects of interleukin-33 and the IL-33 receptor complex. Martin MU. Semin Immunol 25 449-457 (2013)
  22. Interleukin-1 as Innate Mediator of T Cell Immunity. Van Den Eeckhout B, Tavernier J, Gerlo S. Front Immunol 11 621931 (2020)
  23. The Role of Interleukin-1 in the Pathogenesis of Cancer and its Potential as a Therapeutic Target in Clinical Practice. Litmanovich A, Khazim K, Cohen I. Oncol Ther 6 109-127 (2018)
  24. Subversion of cytokine networks by virally encoded decoy receptors. Epperson ML, Lee CA, Fremont DH. Immunol Rev 250 199-215 (2012)
  25. Inflammasome-Dependent Cytokines at the Crossroads of Health and Autoinflammatory Disease. Van Gorp H, Van Opdenbosch N, Lamkanfi M. Cold Spring Harb Perspect Biol 11 a028563 (2019)
  26. p53's Extended Reach: The Mutant p53 Secretome. Pavlakis E, Stiewe T. Biomolecules 10 E307 (2020)
  27. Cell surface receptors. Deller MC, Yvonne Jones E. Curr Opin Struct Biol 10 213-219 (2000)
  28. Type I IL-1 receptor (IL-1RI) as potential new therapeutic target for bronchial asthma. Lee JH, Wang LC, Yu HH, Lin YT, Yang YH, Yang YH, Chiang BL. Mediators Inflamm 2010 567351 (2010)
  29. Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH). Xu X, Poulsen KL, Wu L, Liu S, Miyata T, Song Q, Wei Q, Zhao C, Lin C, Yang J. Signal Transduct Target Ther 7 287 (2022)
  30. Soluble interleukin-1 receptor--reverse signaling in innate immunoregulation. Spörri B, Bickel M, Dobbelaere D, Machado J, Lottaz D. Cytokine Growth Factor Rev 12 27-32 (2001)
  31. Structural Analysis of SARS-CoV-2 ORF8 Protein: Pathogenic and Therapeutic Implications. Valcarcel A, Bensussen A, Álvarez-Buylla ER, Díaz J. Front Genet 12 693227 (2021)
  32. Preparation of Soluble Proteins from Escherichia coli. Wingfield PT. Curr Protoc Protein Sci 78 6.2.1-6.2.22 (2014)
  33. What are the most promising strategies for the therapeutic immunomodulation of allergic diseases? Tokura Y, Röcken M, Clark RA, Haliasos E, Takigawa M, Sinha AA. Exp Dermatol 10 128-37; discussion 138-40 (2001)
  34. Interleukin-1 receptor antagonist: a promising cytokine against human squamous cell carcinomas. Ding Y, Yi J, Wang J, Sun Z. Heliyon 9 e14960 (2023)

Articles citing this publication (78)

  1. IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cells. Ali S, Huber M, Kollewe C, Bischoff SC, Falk W, Martin MU. Proc Natl Acad Sci U S A 104 18660-18665 (2007)
  2. Interrogating protein interaction networks through structural biology. Aloy P, Russell RB, Russell RB. Proc Natl Acad Sci U S A 99 5896-5901 (2002)
  3. The relationship between sequence and interaction divergence in proteins. Aloy P, Ceulemans H, Stark A, Russell RB, Russell RB. J Mol Biol 332 989-998 (2003)
  4. The bacterial cell-division protein ZipA and its interaction with an FtsZ fragment revealed by X-ray crystallography. Mosyak L, Zhang Y, Glasfeld E, Haney S, Stahl M, Seehra J, Somers WS. EMBO J 19 3179-3191 (2000)
  5. A sequence-based map of the nine genes of the human interleukin-1 cluster. Nicklin MJ, Barton JL, Nguyen M, FitzGerald MG, Duff GW, Kornman K. Genomics 79 718-725 (2002)
  6. Research Support, Non-U.S. Gov't Annotating genes with potential roles in the immune system: six new members of the IL-1 family. Dunn E, Sims JE, Nicklin MJ, O'Neill LA. Trends Immunol 22 533-536 (2001)
  7. IL-1H, an interleukin 1-related protein that binds IL-18 receptor/IL-1Rrp. Pan G, Risser P, Mao W, Baldwin DT, Zhong AW, Filvaroff E, Yansura D, Lewis L, Eigenbrot C, Henzel WJ, Vandlen R. Cytokine 13 1-7 (2001)
  8. Interleukin-1 homologues IL-1F7b and IL-18 contain functional mRNA instability elements within the coding region responsive to lipopolysaccharide. Bufler P, Gamboni-Robertson F, Azam T, Kim SH, Dinarello CA. Biochem J 381 503-510 (2004)
  9. Structural insights into the interaction of IL-33 with its receptors. Liu X, Hammel M, He Y, Tainer JA, Jeng US, Zhang L, Wang S, Wang X. Proc Natl Acad Sci U S A 110 14918-14923 (2013)
  10. Structure of IL-33 and its interaction with the ST2 and IL-1RAcP receptors--insight into heterotrimeric IL-1 signaling complexes. Lingel A, Weiss TM, Niebuhr M, Pan B, Appleton BA, Wiesmann C, Bazan JF, Fairbrother WJ. Structure 17 1398-1410 (2009)
  11. MiR-181a regulates inflammation responses in monocytes and macrophages. Xie W, Li M, Xu N, Lv Q, Huang N, He J, Zhang Y. PLoS One 8 e58639 (2013)
  12. Structural insights into the assembly and activation of IL-1β with its receptors. Wang D, Zhang S, Li L, Liu X, Mei K, Wang X. Nat Immunol 11 905-911 (2010)
  13. The structure and binding mode of interleukin-18. Kato Z, Jee J, Shikano H, Mishima M, Ohki I, Ohnishi H, Li A, Hashimoto K, Matsukuma E, Omoya K, Yamamoto Y, Yoneda T, Hara T, Kondo N, Shirakawa M. Nat Struct Biol 10 966-971 (2003)
  14. Structure of the activating IL-1 receptor signaling complex. Thomas C, Bazan JF, Garcia KC. Nat Struct Mol Biol 19 455-457 (2012)
  15. IL1HY1: A novel interleukin-1 receptor antagonist gene. Mulero JJ, Pace AM, Nelken ST, Loeb DB, Correa TR, Drmanac R, Ford JE. Biochem Biophys Res Commun 263 702-706 (1999)
  16. Extracting function from a beta-trefoil folding motif. Gosavi S, Whitford PC, Jennings PA, Onuchic JN. Proc Natl Acad Sci U S A 105 10384-10389 (2008)
  17. Polymorphisms in IL-1beta and IL-1 receptor antagonist genes are associated with myasthenia gravis. Huang D, Pirskanen R, Hjelmström P, Lefvert AK. J Neuroimmunol 81 76-81 (1998)
  18. Identification of a novel IL-1 cytokine family member in teleost fish. Wang T, Bird S, Koussounadis A, Holland JW, Carrington A, Zou J, Secombes CJ. J Immunol 183 962-974 (2009)
  19. Observation of an unexpected third receptor molecule in the crystal structure of human interferon-gamma receptor complex. Thiel DJ, le Du MH, Walter RL, D'Arcy A, Chène C, Fountoulakis M, Garotta G, Winkler FK, Ealick SE. Structure 8 927-936 (2000)
  20. A novel mutation of IL1RN in the deficiency of interleukin-1 receptor antagonist syndrome: description of two unrelated cases from Brazil. Jesus AA, Osman M, Silva CA, Kim PW, Pham TH, Gadina M, Yang B, Bertola DR, Carneiro-Sampaio M, Ferguson PJ, Renshaw BR, Schooley K, Brown M, Al-Dosari A, Al-Alami J, Sims JE, Goldbach-Mansky R, El-Shanti H. Arthritis Rheum 63 4007-4017 (2011)
  21. Multiscale distribution and bioaccumulation analysis of clofazimine reveals a massive immune system-mediated xenobiotic sequestration response. Baik J, Stringer KA, Mane G, Rosania GR. Antimicrob Agents Chemother 57 1218-1230 (2013)
  22. Mutant p53 gains new function in promoting inflammatory signals by repression of the secreted interleukin-1 receptor antagonist. Ubertini V, Norelli G, D'Arcangelo D, Gurtner A, Cesareo E, Baldari S, Gentileschi MP, Piaggio G, Nisticò P, Soddu S, Facchiano A, Bossi G. Oncogene 34 2493-2504 (2015)
  23. Molecular determinants of agonist and antagonist signaling through the IL-36 receptor. Günther S, Sundberg EJ. J Immunol 193 921-930 (2014)
  24. One target-two different binding modes: structural insights into gevokizumab and canakinumab interactions to interleukin-1β. Blech M, Peter D, Fischer P, Bauer MM, Hafner M, Zeeb M, Nar H. J Mol Biol 425 94-111 (2013)
  25. A multidomain flexible docking approach to deal with large conformational changes in the modeling of biomolecular complexes. Karaca E, Bonvin AM. Structure 19 555-565 (2011)
  26. Model of interaction of the IL-1 receptor accessory protein IL-1RAcP with the IL-1beta/IL-1R(I) complex. Casadio R, Frigimelica E, Bossù P, Neumann D, Martin MU, Tagliabue A, Boraschi D. FEBS Lett 499 65-68 (2001)
  27. Engineering protein thermostability using a generic activity-independent biophysical screen inside the cell. Asial I, Cheng YX, Engman H, Dollhopf M, Wu B, Nordlund P, Cornvik T. Nat Commun 4 2901 (2013)
  28. The effects of IL-1 receptor antagonist on beta amyloid mediated depression of LTP in the rat CA1 in vivo. Schmid AW, Lynch MA, Herron CE. Hippocampus 19 670-676 (2009)
  29. Interleukin 1 genotypes in multiple sclerosis and relationship to disease severity. Mann CL, Davies MB, Stevenson VL, Leary SM, Boggild MD, Ko Ko C, Jones PW, Fryer AA, Strange RC, Thompson AJ, Hawkins CP. J Neuroimmunol 129 197-204 (2002)
  30. A New Understanding of the Role of IL-1 in Age-Related Intervertebral Disc Degeneration in a Murine Model. Gorth DJ, Shapiro IM, Risbud MV. J Bone Miner Res 34 1531-1542 (2019)
  31. Soluble interleukin-1 receptor accessory protein ameliorates collagen-induced arthritis by a different mode of action from that of interleukin-1 receptor antagonist. Smeets RL, Joosten LA, Arntz OJ, Bennink MB, Takahashi N, Carlsen H, Martin MU, van den Berg WB, van de Loo FA. Arthritis Rheum 52 2202-2211 (2005)
  32. X-ray crystal structure of a small antagonist peptide bound to interleukin-1 receptor type 1. Vigers GP, Dripps DJ, Edwards CK, Brandhuber BJ. J Biol Chem 275 36927-36933 (2000)
  33. Fanconi anemia C gene product regulates expression of genes involved in differentiation and inflammation. Zanier R, Briot D, Dugas du Villard JA, Sarasin A, Rosselli F. Oncogene 23 5004-5013 (2004)
  34. Kinetic approach to pathway attenuation using XOMA 052, a regulatory therapeutic antibody that modulates interleukin-1beta activity. Roell MK, Issafras H, Bauer RJ, Michelson KS, Mendoza N, Vanegas SI, Gross LM, Larsen PD, Bedinger DH, Bohmann DJ, Nonet GH, Liu N, Lee SR, Handa M, Kantak SS, Horwitz AH, Hunter JJ, Owyang AM, Mirza AM, Corbin JA, White ML. J Biol Chem 285 20607-20614 (2010)
  35. IL-18 receptor beta-induced changes in the presentation of IL-18 binding sites affect ligand binding and signal transduction. Wu C, Sakorafas P, Miller R, McCarthy D, Scesney S, Dixon R, Ghayur T. J Immunol 170 5571-5577 (2003)
  36. A novel mutation in the interleukin-1 receptor antagonist associated with intrauterine disease onset. Altiok E, Aksoy F, Perk Y, Taylan F, Kim PW, Ilıkkan B, Asal GT, Goldbach-Mansky R, Sanal O. Clin Immunol 145 77-81 (2012)
  37. Crystal structure of the Kunitz (STI)-type inhibitor from Delonix regia seeds. Krauchenco S, Pando SC, Marangoni S, Polikarpov I. Biochem Biophys Res Commun 312 1303-1308 (2003)
  38. Pro-inflammatory and anti-inflammatory cytokine increases after spinal instrumentation surgery. Takahashi J, Ebara S, Kamimura M, Kinoshita T, Misawa H, Shimogata M, Tozuka M, Takaoka K. J Spinal Disord Tech 15 294-300 (2002)
  39. Discovery of the DIGIRR gene from teleost fish: a novel Toll-IL-1 receptor family member serving as a negative regulator of IL-1 signaling. Gu YF, Fang Y, Jin Y, Dong WR, Xiang LX, Shao JZ. J Immunol 187 2514-2530 (2011)
  40. Epithelial regulation of mesenchymal tissue behavior. Gallant-Behm CL, Du P, Lin SM, Marucha PT, DiPietro LA, Mustoe TA. J Invest Dermatol 131 892-899 (2011)
  41. Generation and Characterization of Mice Expressing a Conditional Allele of the Interleukin-1 Receptor Type 1. Robson MJ, Zhu CB, Quinlan MA, Botschner DA, Baganz NL, Lindler KM, Thome JG, Hewlett WA, Blakely RD. PLoS One 11 e0150068 (2016)
  42. MARCH3 attenuates IL-1β-triggered inflammation by mediating K48-linked polyubiquitination and degradation of IL-1RI. Lin H, Gao D, Hu MM, Zhang M, Wu XX, Feng L, Xu WH, Yang Q, Zhong X, Wei J, Xu ZS, Zhang HX, Song ZM, Zhou Q, Ye W, Liu Y, Li S, Shu HB. Proc Natl Acad Sci U S A 115 12483-12488 (2018)
  43. Neutralizing epitopes on the extracellular interferon gamma receptor (IFNgammaR) alpha-chain characterized by homolog scanning mutagenesis and X-ray crystal structure of the A6 fab-IFNgammaR1-108 complex. Sogabe S, Stuart F, Henke C, Bridges A, Williams G, Birch A, Winkler FK, Robinson JA. J Mol Biol 273 882-897 (1997)
  44. Engineering endogenous inflammatory cells as delivery vehicles. Kao WJ, Liu Y, Gundloori R, Li J, Lee D, Einerson N, Burmania J, Stevens K. J Control Release 78 219-233 (2002)
  45. Cloning, sequence analysis and crystal structure determination of a miraculin-like protein from Murraya koenigii. Gahloth D, Selvakumar P, Shee C, Kumar P, Sharma AK. Arch Biochem Biophys 494 15-22 (2010)
  46. Computational identification, cloning, and characterization of IL-1R9, a novel interleukin-1 receptor-like gene encoded over an unusually large interval of human chromosome Xq22.2-q22.3. Sana TR, Debets R, Timans JC, Bazan JF, Kastelein RA. Genomics 69 252-262 (2000)
  47. Human IL-1 receptor antagonist from Escherichia coli: large-scale microbial growth and protein purification. Zanette D, Dundon W, Soffientini A, Sottani C, Marinelli F, Akeson A, Sarubbi E. J Biotechnol 64 187-196 (1998)
  48. Understanding the folding-function tradeoff in proteins. Gosavi S. PLoS One 8 e61222 (2013)
  49. Long-range coupling between separate docking sites in interleukin-1beta. Heidary DK, Roy M, Daumy GO, Cong Y, Jennings PA. J Mol Biol 353 1187-1198 (2005)
  50. A dimeric ternary complex of FGFR [correction of FGFR1], heparin and FGF-1 leads to an 'electrostatic sandwich' model for heparin binding. Huhtala MT, Pentikäinen OT, Johnson MS. Structure 7 699-709 (1999)
  51. Effects of IL-1 receptor accessory protein on IL-1 binding. Wesche H, Resch K, Martin MU. FEBS Lett 429 303-306 (1998)
  52. The immunosuppressive activity of peptide fragments of vaccinia virus C10L protein and a hypothesis on the role of this protein in the viral invasion. Kluczyk A, Siemion IZ, Szewczuk Z, Wieczorek Z. Peptides 23 823-834 (2002)
  53. Biophysical characterization of structural properties and folding of interleukin-1 receptor antagonist. Latypov RF, Harvey TS, Liu D, Bondarenko PV, Kohno T, Fachini RA, Rosenfeld RD, Ketchem RR, Brems DN, Raibekas AA. J Mol Biol 368 1187-1201 (2007)
  54. miR-636: A Newly-Identified Actor for the Regulation of Pulmonary Inflammation in Cystic Fibrosis. Bardin P, Foussignière T, Rousselet N, Rebeyrol C, Porter JC, Corvol H, Tabary O. Front Immunol 10 2643 (2019)
  55. DPIE [2-(1,2-diphenyl-1H-indol-3-yl)ethanamine] Augments Pro-Inflammatory Cytokine Production in IL-1β-Stimulated Primary Human Oral Cells. Ahn SH, Lee JK, Kim ND, Kim SH, Lee S, Jung S, Chay KO, Lee TH. Int J Mol Sci 19 E1835 (2018)
  56. SnapDock-template-based docking by Geometric Hashing. Estrin M, Wolfson HJ. Bioinformatics 33 i30-i36 (2017)
  57. Allosteric switching of agonist/antagonist activity by a single point mutation in the interluekin-1 receptor antagonist, IL-1Ra. Hailey KL, Capraro DT, Barkho S, Jennings PA. J Mol Biol 425 2382-2392 (2013)
  58. Characterization of Chenopodin Isoforms from Quinoa Seeds and Assessment of Their Potential Anti-Inflammatory Activity in Caco-2 Cells. Capraro J, De Benedetti S, Di Dio M, Bona E, Abate A, Corsetto PA, Scarafoni A. Biomolecules 10 E795 (2020)
  59. Identification, cloning, and functional characterization of the IL-1 receptor antagonist in the chicken reveal important differences between the chicken and mammals. Gibson MS, Fife M, Bird S, Salmon N, Kaiser P. J Immunol 189 539-550 (2012)
  60. The first two N-terminal immunoglobulin-like domains of soluble human IL-1 receptor type II are sufficient to bind and neutralize IL-1beta. Kollewe C, Neumann D, Martin MU. FEBS Lett 487 189-193 (2000)
  61. Production and characterization of the extracellular domain of recombinant human fibroblast growth factor receptor 4. Loo BB, Darwish KK, Vainikka SS, Saarikettu JJ, Vihko PP, Hermonen JJ, Goldman AA, Alitalo KK, Jalkanen MM. Int J Biochem Cell Biol 32 489-497 (2000)
  62. Structural differences between the putative carbohydrate-recognition domains of human IL-1 alpha, IL-1 beta and IL-1 receptor antagonist obtained by in silico modeling. Vergoten G, Zanetta JP. Glycoconj J 24 183-193 (2007)
  63. A single amino acid difference between human and monkey interleukin (IL)-1beta dictates effective binding to soluble type II IL-1 receptor. Smith DE, Ketchem RR, Moore H, Anderson Z, Renshaw BR, Friend DJ, Sims JE. J Biol Chem 277 47619-47625 (2002)
  64. Comparative analysis of receptor binding by chicken and human interleukin-1β. Cheng CS, Lu WS, Tu IF, Lyu PC, Yin HS. J Mol Model 17 1283-1294 (2011)
  65. Using LongSAGE to Detect Biomarkers of Cervical Cancer Potentially Amenable to Optical Contrast Agent Labelling. Kneller JM, Ehlen T, Matisic JP, Miller D, Van Niekerk D, Lam WL, Marra M, Richards-Kortum R, Follen M, Macaulay C, Jones SJ. Biomark Insights 2 447-461 (2007)
  66. Development of interleukin-1 receptor antagonist mutants with enhanced antagonistic activity in vitro and improved therapeutic efficacy in collagen-induced arthritis. Dahlén E, Barchan K, Herrlander D, Höjman P, Karlsson M, Ljung L, Andersson M, Bäckman E, Hager AC, Walse B, Joosten L, van den Berg W. J Immunotoxicol 5 189-199 (2008)
  67. Differential effects of anti-IL-1R accessory protein antibodies on IL-1alpha or IL-1beta-induced production of PGE(2) and IL-6 from 3T3-L1 cells. Yoon DY, Dinarello CA. J Biochem Mol Biol 40 562-570 (2007)
  68. Temporal gene expression analysis of human coronary artery endothelial cells treated with Simvastatin. Zhang LQ, Ma SF, Grigoryev D, Lavoie TL, Xiao HQ, Setterquist R, Li H, Jacobson J, Garcia JG, Ye SQ. Gene Expr 14 229-239 (2008)
  69. The "two-headed" peptide inhibitors of interleukin-1 action. Kluczyk A, Siemiona IZ, Wieczorek Z. Peptides 21 1411-1420 (2000)
  70. Impact of IL-1β and the IL-1R antagonist on relapse risk and survival in AML patients undergoing immunotherapy for remission maintenance. Grauers Wiktorin H, Aydin E, Christenson K, Issdisai N, Thorén FB, Hellstrand K, Martner A. Oncoimmunology 10 1944538 (2021)
  71. Molecular characterization and functional expression of equine interleukin-1 type I and type II receptor cDNAs. Kirisawa R, Hashimoto N, Tazaki M, Yamanaka H, Ishii R, Hagiwara K, Iwai H. Vet Immunol Immunopathol 109 219-231 (2006)
  72. Influence of L-glutamic acid on binding of interleukin-1beta, tumour necrosis factor-alpha and interleukin-6 to HL-60 cells. Kostanyan IA, Nurieva RI, Navolotskaya EV, Astapova MV, Dranitsina SM, Bogachuk AP, Zav'yalov VP, Lipkin VM. Immunol Lett 62 9-13 (1998)
  73. Outlining key inflammation-associated parameters during early phase of an experimental gram-negative sepsis model in rhesus macaques (Macaca mulatta). Rosado-Franco JJ, Ramos-Benitez MJ, Parodi LM, Rosario D, Compo N, Giavedoni LD, Espino AM. Animal Model Exp Med 2 326-333 (2019)
  74. A two-step selection approach for the identification of ligand-binding determinants in cytokine receptors. Friedrich K, Wietek S, Lischke A, Wellbrock C, Kreitman RJ, Pastan I, Sebald W. Anal Biochem 268 179-186 (1999)
  75. Discovery of a selective and biologically active low-molecular weight antagonist of human interleukin-1β. Hommel U, Hurth K, Rondeau JM, Vulpetti A, Ostermeier D, Boettcher A, Brady JP, Hediger M, Lehmann S, Koch E, Blechschmidt A, Yamamoto R, Tundo Dottorello V, Haenni-Holzinger S, Kaiser C, Lehr P, Lingel A, Mureddu L, Schleberger C, Blank J, Ramage P, Freuler F, Eder J, Bornancin F. Nat Commun 14 5497 (2023)
  76. Evaluation of serum interleukin-1 receptor antagonist levels in major depressive disorder: A case-control study. Nahar Z, Monisha ST, Qusar MS, Islam MR. Health Sci Rep 6 e1175 (2023)
  77. Macrophages as an effector mechanism to reject encapsulated hepatoma cells. Yu SC, Chen JP, Liu HS, Hsu BR, Fu SH. Transplant Proc 32 958-959 (2000)
  78. Structural basis of the IL-1 receptor TIR domain-mediated IL-1 signaling. Zhou J, Xiao Y, Ren Y, Ge J, Wang X. iScience 25 104508 (2022)


Related citations provided by authors (2)

  1. Crystals of Soluble Interleukin-1 Receptor Complexed with its Natural Antagonist Reveal a 1:1 Receptor-Ligand Complex. Schreuder H, Tardif C, Soffientini A, Sarubbi E, Akeson A, Bowlin T, Yanofsky S, Barrett RW FEBS Lett. 373 39- (1995)
  2. Refined Crystal Structure of the Interleukin-1 Receptor Antagonist. Presence of a Disulfide Link and a Cis-Proline. Schreuder HA, Rondeau JM, Tardif C, Soffientini A, Sarubbi E, Akeson A, Bowlin TL, Yanofsky S, Barrett RW Eur. J. Biochem. 227 838- (1995)

Quick links